http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19008231

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article|Research Support, Non-U.S. Gov't
endingPage 1135
issn 1470-2045
issueIdentifier 8
pageRange 1124-1135
publicationName The Lancet. Oncology
startingPage 1124
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4b6e8764c77ccb973bb37b81c833df3b
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_9574ff159e4752ddaa0ba980a53a02f7
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d29184df8844e34b460482b1b6dbad96
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_191c053e42d603729a92cd9f854bd527
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_cbf76ce8c0ac9292cc60b3ed2e234245
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f9d878de052832230a3ba6c5a996d396
bibliographicCitation Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019 Aug;20(8):1124–35. doi: 10.1016/s1470-2045(19)30328-6. PMID: 31257177.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6099-4236
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bdd4cfcca14b6af56d5690419afa8aaa
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b107289fb2e5f4503505714ca3cc77af
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_661dc89d95cb4624eed3990edf81a338
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a00c5498bda325ec3e97e906392507e0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ddf67f6260a128da85e61c37c023337f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1503-3123
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_138d8f385510b2330bb6b1067a7211db
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0eaeaa663e675dc5a804ecfc95e59566
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9c17259c6ced0577ec08be648f62b794
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3b9d595cfdfb617649078ab7c86622dd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7085204eb9223152b0148a9bd32a6c03
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40de55355089c7aff1cb8543ede8b1b9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7860-8417
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_453bbb085c8b6409918323f5d988cd8a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8296-5065
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3417-4274
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7e4a087ecb5eeddbfa8e1f4ac0146746
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4832-7008
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_29dc2f5f7649e83f4384b2af9d15d74c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_151fd7dde8074e81be98d43b1dd21610
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fede2a1a296044cf5bd8574d343a645a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5f58d4fd8a74cd46591d8d37eceed694
date 201908
identifier https://pubmed.ncbi.nlm.nih.gov/31257177
https://doi.org/10.1016/s1470-2045%2819%2930328-6
isPartOf https://portal.issn.org/resource/ISSN/1470-2045
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
discusses http://id.nlm.nih.gov/mesh/M0291428
http://id.nlm.nih.gov/mesh/M0495206
http://id.nlm.nih.gov/mesh/M0001483
http://id.nlm.nih.gov/mesh/M0028048
http://id.nlm.nih.gov/mesh/M000679141
http://id.nlm.nih.gov/mesh/M0028142
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D000970Q000008
http://id.nlm.nih.gov/mesh/D000068878Q000008
http://id.nlm.nih.gov/mesh/D001943Q000188
http://id.nlm.nih.gov/mesh/D009369Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000068878Q000009
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D000970Q000009
http://id.nlm.nih.gov/mesh/D018719Q000096
http://id.nlm.nih.gov/mesh/D018796Q000008
http://id.nlm.nih.gov/mesh/D018796Q000009
http://id.nlm.nih.gov/mesh/D004305
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D020714
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9305
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8221
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9548
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7325
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9975
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID88899540
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10923
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7970
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8911
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9696
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9950

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID178103510

Total number of triples: 88.